Phenotyping Responses to Systemic Corticosteroids in the Management of Asthma Attacks

CompletedOBSERVATIONAL
Enrollment

78

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

April 18, 2024

Study Completion Date

June 13, 2024

Conditions
Asthma
Interventions
OTHER

Visit 1: Clinical exam and questionnaires

Medical history and examination, including vital signs, inhaler technique and adherence check (using prescript refills via the Dossier Santé Québec and/or calls to the community pharmacy), 5-item Asthma Control Questionnaire (ACQ-5), dyspnea rated on the modified Medical Research Council scale (mMRC), visual analog scale (VAS) for six respiratory symptoms, Pittsburgh Vocal Cord Dysfunction Index, Nijmegen Questionnaire, Hospital Anxiety and Depression Scale.

OTHER

Visit 1: Respiratory physiology

FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).

OTHER

Visit 1: Inflammometry

Nasosorption with nasal epithelial lining fluid (NELF), nasal swab for ultrarapid SARS-CoV2 molecular test (ID NOW), nasopharyngeal swab for rapid multiplex PCR viral (BIOFIRE), nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, total and specific serum immunoglobulin E, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank), chest x-ray

OTHER

Visit 2: Clinical exam and questionnaires

Medical history and examination, including vital signs, symptom scores (ACQ-5, mMRC), visual analog scale (VAS) for six respiratory symptoms, Hospital Anxiety and Depression Scale, satisfaction questionnaire about point-of-care biomarker measurements, satisfaction questionnaire about point-of-care biomarker measurements: letter and email sent to treating doctor.

OTHER

Visit 2: Respiratory physiology

FeNO measurement (NIOX VERO device), pre/post-bronchodilator oscillometry (Tremoflo), and spirometry (including forced expiratory volume in 1 second (FEV1) reversibility, FEV1/FVC, peak expiratory flow).

OTHER

Visit 2: Inflammometry

SARS-CoV2 Test (ID NOW), nasosorption, nasal cytology brushes, blood tests (complete blood count with differential, C-reactive protein, biobank), capillary blood eosinophils (Sight OLO), urine sample (creatinine, biobank)

OTHER

Visit 3: e-mail

ACQ-5, peak flow measurement, and questions about the patient's asthma management.

Trial Locations (1)

J1H5N4

Centre de Recherche du CHUS, Sherbrooke

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi-Regeneron

UNKNOWN

collaborator

Réseau de Recherche en Santé Respiratoire du Québec

UNKNOWN

collaborator

Association Pulmonaire du Quebec

OTHER

collaborator

BioMérieux

INDUSTRY

collaborator

Fonds de la Recherche en Santé du Québec

OTHER_GOV

lead

Université de Sherbrooke

OTHER